CD31 expression in human cancers: a pan-cancer immunohistochemical study

Area of Science:

• Oncology
• Molecular Biology
• Immunohistochemistry

Background:

• CD31 (platelet endothelial cell adhesion molecule 1) is a glycoprotein involved in cell adhesion and signal transduction.
• It is typically expressed in vascular endothelial cells, platelets, and neutrophils.
• CD31 expression in cancer cells is not fully understood.

Purpose of the Study:

• To investigate CD31 expression in various cancer types.
• To determine the frequency and distribution of CD31 in cancer cell lines and patient specimens.
• To assess the diagnostic significance of CD31 expression in cancer.

Main Methods:

• Pan-cancer gene expression analysis of 1073 cancer cell lines.
• Immunohistochemical analysis of 358 surgically resected cancer specimens.
• Comparison of CD31 expression frequency across cancer subtypes and histological types.

Main Results:

• Adenocarcinomas exhibited higher CD31 expression frequency than squamous cell carcinomas in gene expression analysis.
• Immunohistochemistry revealed CD31 expression in breast apocrine (40.0%), uterine endometrioid (31.6%), ovarian clear cell (40.0%), and urothelial carcinomas (25.0%).
• CD31 expression was not detected in esophageal, renal, prostate, or cervical cancers.

Conclusions:

• CD31 expression is more frequent in adenocarcinomas than squamous cell carcinomas, with significant subtype variability.
• Accurate identification of CD31-positive cancers is essential to avoid misdiagnosis as endothelial-derived tumors.
• Further research is needed to elucidate the mechanisms of CD31 expression in cancer.